Stablecoin Development Corp

NBY · NYSE · SIC 2834: Pharmaceutical Preparations
348
SEC Filings

Business Summary

PART I Overview We have undergone significant changes to our business and operations as a result of a series of completed transactions summarized below and discussed in further detail under the next section titled Recent Developments below. As a result of these transactions, we have significantly reduced our legacy pharmaceutical business operations and have adopted a new strategic direction as a business, shifting to a capital allocation strategy that focuses on acquiring digital assets that pr...

Next Earnings

Q2 FY2026 — expected 2026-09-20

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionNBYdiscussed_in_filing Cybersecurity
topic_mentionNBYdiscussed_in_filing Blockchain & Crypto
topic_mentionNBYdiscussed_in_filing Enterprise
topic_mentionNBYdiscussed_in_filing Cybersecurity
topic_mentionNBYdiscussed_in_filing Blockchain & Crypto
topic_mentionNBYdiscussed_in_filing Enterprise
topic_mentionNBYdiscussed_in_filing Cybersecurity
topic_mentionNBYdiscussed_in_filing Blockchain & Crypto
topic_mentionNBYdiscussed_in_filing Enterprise
topic_mentionNBYdiscussed_in_filing Healthcare & Bio
topic_mentionNBYdiscussed_in_filing Cybersecurity
topic_mentionNBYdiscussed_in_filing Blockchain & Crypto
topic_mentionNBYdiscussed_in_filing Enterprise
topic_mentionNBYdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310001437749-26-009090EDGAR77K words
2025-04-022024-12-310001437749-25-010730EDGAR
2024-03-262023-12-310001437749-24-009417EDGAR
2023-03-312022-12-310001437749-23-008843EDGAR
2022-03-292021-12-310001437749-22-007543EDGAR
2021-03-252020-12-310001437749-21-007158EDGAR
2020-03-262019-12-310001437749-20-006213EDGAR
2019-03-292018-12-310001437749-19-006017EDGAR
2018-03-212017-12-310001437749-18-005177EDGAR
2017-03-232016-12-310001437749-17-005131EDGAR

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-072025-09-300001437749-25-033852EDGAR36K words
2025-08-142025-06-300001437749-25-026970EDGAR
2025-05-152025-03-310001437749-25-017064EDGAR
2024-11-072024-09-300001437749-24-033919EDGAR
2024-08-132024-06-300001437749-24-026386EDGAR
2024-05-092024-03-310001437749-24-015679EDGAR
2023-11-092023-09-300001437749-23-031256EDGAR
2023-08-102023-06-300001437749-23-023110EDGAR
2023-05-112023-03-310001437749-23-013945EDGAR
2022-11-142022-09-300001437749-22-027275EDGAR
2022-08-112022-06-300001437749-22-020119EDGAR
2022-05-122022-03-310001437749-22-012124EDGAR

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-060001437749-26-011312EDGAR1K words
2026-04-010001437749-26-010902EDGAR
2026-03-230001437749-26-009301EDGAR
2026-03-120001437749-26-008015EDGAR
2026-02-200001437749-26-004922EDGAR
2026-02-120001437749-26-003846EDGAR
2026-01-300001437749-26-002586EDGAR
2026-01-280001437749-26-002309EDGAR
2026-01-200001437749-26-001490EDGAR
2026-01-160001437749-26-001459EDGAR

348 total filings indexed. 316 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001389545
TickerNBY
ExchangeNYSE
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 001fd420e75b16361ade3460de77a88b6e2c6c7c459f5cdce035e500158c6a2c
parent: ed9f0b5ea83f1db23d1256439e29afc9064f5874dd9af93be7c1cb4ba50e7f51
content hash: 6f2e30c511650598a8d56b64171d0d2d85580eeb499cb80558144694cef68276
signed: 2026-04-13T04:46:27.063Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf